Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Rating of “Moderate Buy” from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $63.40.

A number of research analysts have commented on the company. Stifel Nicolaus assumed coverage on Enliven Therapeutics in a research note on Tuesday, June 9th. They set a “buy” rating and a $60.00 price target on the stock. Guggenheim assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target on the stock. Mizuho increased their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. The Goldman Sachs Group increased their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th.

Enliven Therapeutics Trading Up 2.8%

Shares of ELVN stock opened at $49.12 on Friday. The company’s 50-day moving average price is $42.05 and its 200-day moving average price is $32.34. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of -29.41 and a beta of 0.29. Enliven Therapeutics has a twelve month low of $14.78 and a twelve month high of $50.56.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities research analysts predict that Enliven Therapeutics will post -1.71 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. This trade represents a 16.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. The trade was a 10.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. Vestal Point Capital LP increased its holdings in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the period. Siren L.L.C. acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at $29,252,000. Affinity Asset Advisors LLC acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at $23,007,000. TCG Crossover Management LLC acquired a new position in shares of Enliven Therapeutics in the 2nd quarter valued at $9,990,000. Finally, Duquesne Family Office LLC increased its holdings in shares of Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after acquiring an additional 484,405 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.